[Botulinum toxin (BoNT) : Short form of a European consensus panel report regarding recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions].
Botulinum toxin A has still not been approved for urologic indications leading to uncertainty of the user or those who would like to use it. Recently, a report of a European consensus panel on this topic was published in European Urology: Apostolidis et al. (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus panel report. As there is general interest in this treatment the German translation of this report should facilitate access to the most relevant information. This very condensed article focuses on the clinical practical features and is not a precise word-by-word translation but should serve as concise guidelines for the German-speaking colleagues who are involved with this treatment. Further detailed information (e.g. pharmacology, exact mode of action, tables and references etc.) is available in the very extensive original manuscript.
Schulte-Baukloh
H
H
Abteilung für Urologie, St. Hedwig-Krankenhaus, Grosse Hamburger Strasse 5-11, 10115, Berlin, Deutschland. H.Schulte-Baukloh@alexius.de
D001905:Botulinum Toxins / Q000627:therapeutic use*; D003245:Consensus Statements as Topic; D005060:Europe; D005242:Fecal Incontinence / Q000188:drug therapy*; D006801:Humans; D017773:Pelvic Floor; D017410:Practice Guidelines as Topic; D014570:Urologic Diseases / Q000188:drug therapy*
D001905:Botulinum Toxins